Trial Profile
A study of COR-003 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs Levoketoconazole (Primary) ; Atorvastatin; Ketoconazole
- Indications Cushing syndrome
- Focus Adverse reactions; Pharmacokinetics
- 10 May 2018 According to a Strongbridge Biopharma media release,Presented results from an in vitro study of levoketoconazole, the active ingredient in RECORLEV, at ENDO 2018, the Annual Meeting of the Endocrine Society
- 06 Apr 2016 New trial record
- 04 Apr 2016 According to a Strongbridge Biopharma media release, results from this study were presented at the Endocrine Society's 2016 Annual Meeting and Expo.